[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edward M. Kaye, M.D., a director of Stoke Therapeutics, Inc. (STOK), reported equity awards and stock units on 08/14/2025. The filing shows an acquisition of 26,250 shares of common stock and that Dr. Kaye beneficially owned 165,596 shares after the transaction. He was also granted performance stock units convertible into 52,500 shares and an additional 26,250 performance stock units, each with an exercise/conversion price of $0. The performance units vest in two equal installments: one on August 14, 2025 and the remainder on August 14, 2026, subject to continued service and certification of performance conditions. The form was signed by an attorney-in-fact on 08/18/2025.

Positive

• Director alignment with shareholders: awards are performance-based and vest over two years, tying compensation to continued service and committee-certified performance.
• Clear vesting schedule: half vests on 08/14/2025 and the remainder on 08/14/2026, providing transparent timing for potential share delivery.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received stock and performance units, increasing his reported stake without cash purchase; modest corporate governance signal.

Dr. Kaye acquired 26,250 shares and was granted a total of 78,750 performance stock units convertible one-for-one into common shares at $0, which vest half on 08/14/2025 and half on 08/14/2026 subject to service and performance certification. This increases his reported beneficial ownership to 165,596 shares. From an investor perspective, awards tied to performance criteria align management incentives with shareholder outcomes, but the filing does not disclose the specific performance metrics or the proportionate dilutive effect relative to outstanding shares.

Corporate Governance Expert

TL;DR: Standard equity-based compensation for a director; important to review performance conditions and timing.

The report documents restricted/performance stock units and a direct acquisition recorded 08/14/2025. Vesting is time-staggered across 2025 and 2026 and contingent on certification of performance by the compensation committee. This is a routine mechanism to retain and incentivize a director, but shareholders should review proxy disclosures for the underlying performance criteria to assess governance implications and alignment with long-term shareholder value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		M		26,250	A	$0	165,596	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	08/14/2025		A(2)		52,500		(3)	08/14/2026	Common Stock	52,500	$0	52,500	D
Performance Stock Units	(1)	08/14/2025		M			26,250	(3)	08/14/2026	Common Stock	26,250	$0	26,250	D

Explanation of Responses:

1. Each performance stock unit represents a right to receive one share of the Issuer's common stock.

2. This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

3. Half the award vests on August 14, 2025 and the remainder shall vest on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Stoke Therapeutics (STOK) director Edward M. Kaye acquire on 08/14/2025?

He acquired 26,250 shares of common stock and was granted performance stock units convertible into 78,750 shares in total (52,500 and 26,250 unit awards).

How many shares does Edward M. Kaye beneficially own after the reported transaction?

The filing reports that he beneficially owned 165,596 shares following the transaction.

What are the vesting terms for the performance stock units reported for STOK?

Half of the performance stock units vest on August 14, 2025 and the remainder vests on August 14, 2026, subject to continued service and certification of performance criteria.

What is the conversion/exercise price for the performance stock units?

The performance stock units are reported with a conversion/price of $0, representing restricted units convertible one-for-one into common stock upon vesting.

Who signed the Form 4 for Edward M. Kaye and when?

The Form 4 was signed by Jonathan Allan, Attorney-in-Fact on 08/18/2025.